How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: The case of Luangwa District, Zambia.
Adult
Aged
Aged, 80 and over
Community Participation
Disease Transmission, Infectious
/ prevention & control
Elephantiasis, Filarial
/ drug therapy
Female
Filaricides
/ therapeutic use
Health Education
Health Knowledge, Attitudes, Practice
Humans
Male
Mass Drug Administration
/ methods
Middle Aged
Young Adult
Zambia
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
08
02
2019
accepted:
21
10
2019
revised:
11
12
2019
pubmed:
28
11
2019
medline:
12
2
2020
entrez:
28
11
2019
Statut:
epublish
Résumé
The success of the global strategy to eliminate lymphatic filariasis (LF) through mass drug administration (MDA) campaigns is dependent on meeting high coverage levels over long periods of time. Community engagement plays a critical role in driving coverage and involvement of local communities in MDA for LF. This study explored how community engagement approaches used in MDA for LF shape participation in the programme, with a view of proposing effective engagement strategies. The study was conducted in Luangwa, a rural District of Lusaka province, Zambia. An exploratory qualitative case study approach was employed. A total of nine focus group discussions, six in-depth and seven key informant interviews were conducted with various participants that included; community members, traditional leaders and programme managers, respectively. Data were analysed using a thematic approach, aided by NVivo 10 software. Three core thematic areas emerged from the data as priority focus areas for programme planners and implementers in designing effective community engagement strategies that facilitate participation. Firstly, employing of partnership approaches through adequate and timely engagement of traditional, government and non-governmental organisation structures. Secondly, use of appropriate and innovative health education initiatives to disseminate information about the programme. Thirdly, addressing context specific programme implementation barriers affecting community engagement in MDA for LF. Facilitating participation in MDA for LF will require designing and implementing effective community engagement strategies that take into account local context, but also seek to explore all avenues of maximizing participation for improved coverage levels. MDA for LF implementation teams should systematically consider the identified factors and seek to incorporate them in their implementation plans.
Sections du résumé
BACKGROUND
The success of the global strategy to eliminate lymphatic filariasis (LF) through mass drug administration (MDA) campaigns is dependent on meeting high coverage levels over long periods of time. Community engagement plays a critical role in driving coverage and involvement of local communities in MDA for LF. This study explored how community engagement approaches used in MDA for LF shape participation in the programme, with a view of proposing effective engagement strategies.
METHODS
The study was conducted in Luangwa, a rural District of Lusaka province, Zambia. An exploratory qualitative case study approach was employed. A total of nine focus group discussions, six in-depth and seven key informant interviews were conducted with various participants that included; community members, traditional leaders and programme managers, respectively. Data were analysed using a thematic approach, aided by NVivo 10 software.
RESULTS
Three core thematic areas emerged from the data as priority focus areas for programme planners and implementers in designing effective community engagement strategies that facilitate participation. Firstly, employing of partnership approaches through adequate and timely engagement of traditional, government and non-governmental organisation structures. Secondly, use of appropriate and innovative health education initiatives to disseminate information about the programme. Thirdly, addressing context specific programme implementation barriers affecting community engagement in MDA for LF.
CONCLUSION
Facilitating participation in MDA for LF will require designing and implementing effective community engagement strategies that take into account local context, but also seek to explore all avenues of maximizing participation for improved coverage levels. MDA for LF implementation teams should systematically consider the identified factors and seek to incorporate them in their implementation plans.
Identifiants
pubmed: 31774820
doi: 10.1371/journal.pntd.0007861
pii: PNTD-D-19-00200
pmc: PMC6905562
doi:
Substances chimiques
Filaricides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0007861Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS Negl Trop Dis. 2011 Oct;5(10):e1346
pubmed: 22022627
Health Res Policy Syst. 2010 Oct 21;8:32
pubmed: 20961461
Infect Dis Poverty. 2014 Sep 01;3:31
pubmed: 25237478
Lancet Glob Health. 2016 Mar;4(3):e154-5
pubmed: 26874545
Malar J. 2016 Nov 2;15(1):523
pubmed: 27806717
PLoS Negl Trop Dis. 2013 Apr 11;7(4):e2080
pubmed: 23593512
Am J Trop Med Hyg. 2002 Sep;67(3):266-72
pubmed: 12408665
Parasit Vectors. 2013 Oct 15;6(1):299
pubmed: 24499525
Philos Trans R Soc Lond B Biol Sci. 2013 Jun 24;368(1623):20120137
pubmed: 23798686
Parasit Vectors. 2010 Dec 16;3:120
pubmed: 21162751
PLoS Negl Trop Dis. 2012;6(3):e1574
pubmed: 22448294
Philos Trans R Soc Lond B Biol Sci. 2013 Jun 24;368(1623):20120144
pubmed: 23798692
Malar J. 2017 Feb 14;16(1):75
pubmed: 28196536
PLoS Negl Trop Dis. 2014 Feb 20;8(2):e2714
pubmed: 24587466
Lancet Infect Dis. 2017 Apr;17(4):358-359
pubmed: 28012944
Adv Parasitol. 2006;61:395-441
pubmed: 16735170
Acta Trop. 2018 Mar;179:109-116
pubmed: 29224979
BMC Public Health. 2008 Oct 01;8:343
pubmed: 18826655
Malar J. 2011 Aug 04;10:225
pubmed: 21816085
BMC Public Health. 2018 Feb 13;18(1):238
pubmed: 29433461
PLoS One. 2012;7(11):e48395
pubmed: 23185256
J Behav Health Serv Res. 2017 Apr;44(2):177-194
pubmed: 26289563
BMC Public Health. 2017 May 22;17(1):484
pubmed: 28532397
J Biosoc Sci. 2016 Jan;48(1):94-112
pubmed: 25790081
Res Rep Trop Med. 2018 Mar 06;9:25-33
pubmed: 30050352
Lancet. 2010 Jan 2;375(9708):67-76
pubmed: 20109865
Curr Pharm Biotechnol. 2012 May;13(6):1110-9
pubmed: 22039801
PLoS Negl Trop Dis. 2009 Aug 25;3(8):e412
pubmed: 19707588